Brief: Achieve Life Sciences Announces FDA Acceptance Of Cytisinicline New Drug Application For Treatment Of Nicotine Dependence For Smoking Cessation
03/09/2025 13:35
Sept 3 (Reuters) - Achieve Life Sciences Inc ACHV.O: ACHIEVE LIFE SCIENCES ANNOUNCES FDA ACCEPTANCE OF CYTISINICLINE NEW DRUG APPLICATION FOR TREATMENT OF NICOTINE DEPENDENCE FOR SMOKING CESSATION ACHIEVE LIFE SCIENCES INC - PDUFA TARGETED DATE SET FOR JUNE 20, 2026 Source text: ID:nGNX4wbw1B Further company coverage: ACHV.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Achieve Life Sciences
See all newsAchieve Life Sciences Q3 net loss and loss per share beat estimates
Brief: Achieve Life Sciences Presents 52-Week Cytisinicline Results For Smoking And Vaping Cessation At Chest 2026
Brief: Lisata Therapeutics Appoints Jeff Farrow To Board Of Directors
Brief: Achieve Life Sciences Appoints Kaitlyn Tuson As Senior Vice President, Marketing And Communications
Brief: Achieve Life Sciences - Enters ATM Sale Agreement With Jefferies For Up To $150 Million In Common Stock